## Supplementary Table 1. Randomized Controlled Trials Examining the Effect of Pharmacist Intervention on Blood Pressure Management in Diabetes as the Primary Outcome (Study Characteristics)

| Study | Setting / Inclusion Criteria / Sample Size Estimate | \# Patients (withdrawals) | Duration (months) | Pharmacist's Activities |
| :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & \text { Rothman RL, } \\ & 2005 \\ & \text { USA } \end{aligned}$ | University-based General Internal <br> Medicine Practice <br> Patient referred to a Pharmacist-led <br> diabetes management clinic $\mathrm{A}_{1} \mathrm{c} \geq 8 \%$ <br> Based on 10 mmHg difference in SBP and $1 \%$ absolute difference in A1c | $\begin{aligned} & 217 \\ & (23[11 \%]) \end{aligned}$ | 12 | - 3 specially trained (Certified Diabetes Educator) pharmacists <br> - 1-hour patient educational session <br> - Evidence-based treatment algorithms for BG, BP, lipids <br> - Follow-up every 2-4 weeks either by phone or in-person <br> - Medication changes made by pharmacists through a collaborative agreement for prescriptive authority |
| McLean DL, 2008 Canada | Pharmacist-Nurse team in community pharmacies $\mathrm{BP}>130 / 80$ <br> Based on 10 mmHg difference in SBP | $\begin{aligned} & 227 \\ & (16[7 \%]) \end{aligned}$ | 6 | - Pharmacist-Nurse team provided education on BP: as a risk factor, causes of high BP , consequences of high BP , diabetes\& BP, lifestyle strategies to decrease BP <br> - Medication management recommendations sent to physician |
| Planas, 2009 USA | Community pharmacies <br> Sub-study of a diabetes management study <br> A1c>7\% (main study) <br> $\mathrm{BP} \geq 130 / 80$ or using an <br> antihypertensive medication <br> Sample size not estimated | $\begin{aligned} & 52 \\ & (12[24 \%]) \end{aligned}$ | 9 | - Medication therapy management program <br> - Brief physical exam with BP measurement <br> - Education on role of medications \& encouraged adherence <br> - Medication management recommendations sent to physician |

Supplementary Figure 1. Systolic Blood Pressure Changes (Primary Outcome) in Randomized Controlled Trials of Pharmacist Intervention in Diabetes Management


## Supplementary Table 2. Changes in Cardiovascular Risk Factors

| Parameter | Mean Change from Baseline* (95\% CI) | Mean Difference $\dagger$ |  |
| :--- | :--- | :--- | :--- |
|  | Control Group | Intervention Group | (95\% CI) |
| A1c (\%) | $0.03(-0.22$ to 0.28$)$ | $-0.15(-0.36$ to 0.05$)$ | $-0.18(-0.51$ to 0.14$)$ |
| Systolic BP (mmHg) | $-2.5(-5.2$ to 0.1$)$ | $-7.4(-10.2$ to -4.6$) \ddagger$ | $-4.9(-8.7$ to -1.0$) \S$ |
| Diastolic BP (mmHg) | $0.6(-1.4$ to 2.6$)$ | $-2.3(-4.3$ to -0.4$) \ddagger$ | $-2.9(-5.6$ to -0.2$) \S$ |
| Total Cholesterol (mmol/L) | $-0.09(-0.25$ to 0.07$)$ | $-0.23(-0.41$ to -0.05$) \ddagger$ | $-0.14(-0.38$ to 0.10$)$ |
| LDL (mmol/L) | $-0.10(-0.24$ to 0.05$)$ | $-0.23(-0.38$ to -0.08$) \ddagger$ | $-0.14(-0.33$ to 0.07$)$ |
| HDL (mmol/L) | $0.02(-0.01$ to 0.06$)$ | $0.01(-0.02$ to 0.04$)$ | $-0.02(-0.06$ to 0.03$)$ |
| Triglycerides (mmol/L) | $0.09(-0.09$ to 0.27$)$ | $-0.09(-0.26$ to 0.07$)$ | $-0.18(-0.43$ to 0.06$)$ |
| Total/HDL Ratio | $-0.16(-0.29$ to -0.03$) \ddagger$ | $-0.25(-0.39$ to -0.11$) \ddagger$ | $-0.09(-0.28$ to 0.11$)$ |
| UKPDS Risk Engine Score(19) (\%) | $-1.2(-2.4$ to 0.1$)$ | $-2.7(-3.9$ to -1.5$) \ddagger$ | $-1.5(-3.3$ to 0.2$) \\|$ |

95\% CI = 95\% Confidence Interval; BP = Blood Pressure; LDL = Low Density Lipoprotein; HDL = High Density Lipoprotein
*Negative values indicate decrease from baseline, Positive values indicate increase from baseline
$\dagger$ Negative values indicate Intervention Group has larger change, Positive values indicate Control Group has larger change
$\ddagger$ paired t-test, $\mathrm{p}<0.05$
§ANOVA, $\mathrm{p}<0.05$
||Mann-Whitney U, p<0.05

Supplementary Figure 2. Proportion of Subjects Who had Changes to Their Antihypertensive Medications

*p<0.05 (Chi Square)

## Supplementary Table 3. Healthcare-Related Contacts Recorded During Study

| Healthcare Resource | Intervention ( $\mathrm{n}=131$ ) |  |  | Control ( $\mathrm{n}=129$ ) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Number of <br> Patients with <br> $\geq 1$ Contact | Total <br> Number <br> of Contacts | Contacts <br> Per Patient* | Number of <br> Patients with <br> $\geq 1$ Contact | Total <br> Number <br> of Contacts | Contacts <br> Per Patient* |
| All Resources $\dagger$ | 131 | 1439 | 10 (7-15) | 129 | 438 | 2 (2-4) |
| All Resources <br> (excluding pharmacists) | 131 | 238 | 3 (1-6) | 129 | 197 | 2 (2-5) |
| Study Pharmacist $\dagger$ | 131 | 1201 | 9 (6-12) | 129 | 241 | 2 (2-2) |
| Nurse | 18 (14\%) | 47 | 2 (1-4) | 28 (22\%) | 47 | 2 (1-3) |
| Dietician | 10 (8\%) | 16 | 1 (1-2) | 13 (10\%) | 15 | 1 (1-2) |
| Optometrist | 30 (23\%) | 38 | 1 (1-1) | 25 (19\%) | 22 | 1 (1-1) |
| Podiatrist | 8 (6\%) | 31 | 3 (1-6) | 6 (5\%) | 7 | 1 (1-1) |
| Endocrinologist | 5 (4\%) | 13 | 3 (2-3) | 9 (7\%) | 18 | 2 (1-2) |
| Cardiologist | 5 (4\%) | 8 | 1 (1-2) | 8 (6\%) | 15 | 1 (1-2) |
| Nephrologist | 4 (3\%) | 7 | $2(2-2)$ | 1 (1\%) | 2 | 2 |
| Ophthalmologist | 31 (24\%) | 42 | 1 (1-1) | 39 (30\%) | 47 | 1 (1-1) |
| Diabetes Education <br> Centre | 3 (2\%) | 4 | 1 (1-2) | 7 (5\%) | 8 | 1 (1-1) |
| Health Link | 1 (1\%) | 1 | 1 | 1 | 1 | 1 |
| Emergency Room Visit | 11 (8\%) | 26 | 1 (1-3) | 11 (9\%) | 11 | 1 (1-1) |
| Hospitalization | 4 (3\%) | 5 | 1 (1-2) | 5 (4\%) | 4 | 1 (1-1) |

*Reported as Median (Interquartile Range) per patient
$\dagger$ Mann-Whitney U Test ( $\mathrm{p}<0.01$ )

